Skip to main navigationSkip to main content
The University of Southampton
SAFA study

Researchers and Clinicians

The SAFA trial is funded by the NIHR HTA programme to determine the clinical and cost-effectiveness spironolactone compared with placebo in addition to standard care in the treatment of moderate or severe persistent facial acne in adult women.

SAFA is a pragmatic multicentre double-blind randomised placebo-controlled trial recruiting from six dermatology centres in Birmingham, Bristol, Epsom, Harrogate, Poole and Portsmouth. General practices local to the sites will act as Participant Identification Centres.

We plan to recruit 434 women aged 18 years and over.

Recruitment begins in June 2019 and we expect to produce our final report in September 2021. Please see the protocol for more details about how we are carrying out the trial. Please see the Spironolactone Information Sheet if you would like to know more about the trial drug.

Useful Downloads

Need the software?PDF Reader
Privacy Settings